Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Obstetrics and Gynecology Clinics of North America|March 15, 2002
Adjuvant therapy in breast cancerRobert D Legare, Rochelle Strenger
Obstetrics and Gynecology Clinics of North America|March 15, 2002
Risk factors for breast cancerStephen S Falkenberry, Robert D Legare
Seminars in Radiation Oncology|December 1, 2015
Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015Sabrina Witherby, Tina Rizack, Bachir J Sakr, et al.
Gynecologic Oncology|October 4, 2005
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers programDon S Dizon, Joanna Schwartz, Adam Rojan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group StudyWilliam M Sikov, Don S Dizon, Rochelle Strenger, et al.
Gynecologic Oncology|January 1, 2010
Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer programLindsay Kuroki, Ashley Stuckey, Priya Hirway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2015
Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical TrialLawrence G Lum, Archana Thakur, Zaid Al-Kadhimi, et al.
Breast Cancer Research : BCR|February 13, 2010
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic featuresNadine Tung, Yihong Wang, Laura C Collins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)Nadine Tung, Banu Arun, Michele R Hacker, et al.
Breast Cancer Research : BCR|November 18, 2010
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersNadine Tung, Alexander Miron, Stuart J Schnitt, et al.
Pageof 2